INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

Similar documents
Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

[I.5.B.] [III.1.B.] [III.2.C.]

ORC Sponsor-Investigator IDE Checklist

Investigational New Drug Application

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.

Title: Review of Medical Devices Page: 1 of 5 Written by:

Office for Human Subject Protection. University of Rochester

How to put together an IND application

Standard Operating Procedures Guidelines for Good Clinical Practice

Sponsor-Investigator Responsibilities In Clinical Trials

Human Research Protection Program Policy

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

11.0 FDA-Regulated Research

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Bioresearch Monitoring Inspections in Vitro Diagnostics Devices

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

Guidance on Requirements of the Sponsor and the Investigator as a Sponsor

UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device

ELEMENTS OF A DATA MONITORING PLAN

Clinical Trials Management for Molecular Diagnostics. April 2016

INVESTIGATIONAL DEVICE EXEMPTIONS AND EARLY FEASIBILITY STUDIES TO SUPPORT DEVICE INNOVATION

Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

Human Research Protection Program Policy

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

FDA Sponsor and Investigator Responsibility Checklist

IDE Submissions for Devices Used to Manufacture Cell Therapy Products

GCP Basics - refresher

Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form

Sponsor/Investigator Responsibilities

Investigator-Initiated Research

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Investigational New Drug Development Steps for CRCs

Volunteering for Clinical Trials

Guidance for IRBs, Clinical Investigators and Sponsors

Conducted Under an IND to Support a

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Draft Guidance for Industry and Food and Drug Administration Staff

MCW Office of Research Standard Operating Procedure

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition)

IND Development Process Published on ResearchGo UCLA (

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Agency Information Collection Activities; Submission for Office of Management and Budget

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

Investigator s Handbook

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011

MANUAL: Administrative Policy & Procedure Manual POLICY:

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection

Table of Contents Adverse Event Reporting SOPs for Medical Devices

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit

Applicability of US Regulations to Canadian Research

VCU Faculty Held IND and IDE Procedure Handbook

Research: An Essential Component of a Comprehensive MS Center

Requirements for Humanitarian Use Device (HUD)

HUMANITARIAN USE DEVICES 3/8/2016

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer

WCG ACADEMY COURSE OVERVIEW

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.

NIH Forms E Changes for Human Subject and/or Clinical Trial Applications Attached are the Forms E application pages with the most significant changes

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

Investigator-Initiated INDs

PHS Human Subjects and Clinical Trials Information

FDA > CDRH > CFR Title 21 Database Search

The Intersection of Genomics Research and the IDE Regulation

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

Compassionate Use Navigator Information for Physicians

FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers

Technical Guidance on Clinical Evaluation of Medical Devices

Guidelines for Setting Up a Regulatory Binder

Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation

The Institutional Review Board (IRB) Manual

FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations

Sponsoring an IND? Ignorance is Not Always Blissful

University of California, Irvine Human Research Protections Standard Operating Policies and Procedures

1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:

Role of Academic Investigators in Drug Development

Streamlining IRB Procedures for Expanded Access

DATA SHARING AGREEMENT

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB

Regulatory issues for academicled multinational trials in Asia: Who takes responsibility?

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

Views of a Clinical Study Report

Anatomy of an FDA Audit Trigger Prevention and Process

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Guidance for Industry Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans

FORM 5 University of California, Davis Health System Health Physics Office HUMAN RADIATION USE RESEARCH APPLICATION

Expanded Access and the Individual Patient IND

Medical Device Regulations

Human Research Protection Program. Investigator Manual

Technical Guidance on Clinical Evaluation of Medical Devices 1

Transcription:

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version date: 7/2/2013

Table of Contents 1 Name and the address of the sponsor... 3 2 Report of Prior Investigations... 3 2.1.1 General... 3 2.1.2 Specific Content... 3 3 Investigational Plan... 4 3.1.1 Purpose... 4 3.1.2 Protocol... 5 3.1.3 Risk Analysis... 6 3.1.4 Description of Device... 6 3.1.5 Monitoring Plan... 6 4 Manufacturing Information... 7 5 Example of the Investigators Agreement... 8 6 Investigator certification... 9 7 IRB s Information... 10 8 Name and Address of the Investigational Institutions... 11 9 Financial claims... 12 10 Environmental assessment... 13 11 Labeling... 14 12 Informed Consent... 15 13 Additional Information... 16 Page 2 of 16

1 NAME AND THE ADDRESS OF THE SPONSOR 2 REPORT OF PRIOR INVESTIGATIONS In this section, sponsor should provide a complete report of prior investigations of the device. 2.1.1 General The report of prior investigations shall include reports of all prior clinical, animal, and laboratory testing of the device and shall be comprehensive and adequate to justify the proposed investigation. 2.1.2 Specific Content a) A bibliography of all publications, whether adverse of supportive, that are relevant to an evaluation of the safety or effectiveness of the device, copies of all published and unpublished adverse information, and, if requested by an IRB or FDA, copies of other significant publications. b) A summary of all other unpublished information (whether adverse or supportive) in the possession of, or reasonably obtainable by, the sponsor that is relevant to an evaluation of safety or effectiveness of the device. c) If information on nonclinical laboratory studies is provided a statement that all such studies have been conducted in compliance with applicable requirements in the good laboratory practice (GLP) regulation in 21 CRF part 58. If the study was not conducted in compliance with such regulations, a brief statement of the reason for the non compliance. Page 3 of 16

3 INVESTIGATIONAL PLAN At the beginning of this section, sponsor can give a brief overview of the investigation plan, logic and need for this trial, is it a single-site study, what are the end points etc.. 3.1.1 Purpose The name and intended use of the device and the objectives and duration of the investigations. Page 4 of 16

3.1.2 Protocol A written protocol should describe the methodology to be used and an analysis of the protocol demonstrating that the investigation is scientifically sound. Protocol should include objectives and the hypothesis of the trial. Also describe the type of trial (i.e., controlled/open, double-blind/single/blind, etc.).describe in details how the trial will be conducted and analytical methods that will be used to evaluate the study. If case report forms (CFR) will be used, please attach it to the protocol. Page 5 of 16

3.1.3 Risk Analysis A description and analysis of all increased risks to which subject will be exposed by the investigation; the manner in which these risk will be minimized; a justification for the investigation; and a description of the patient population including the number, age, sex, and condition. 3.1.4 Description of Device A description of each important component, ingredient, property and principle of operation of the device and of each anticipated change in the device during the course of investigation 3.1.5 Monitoring Plan The sponsor s written procedures for monitoring the investigation and the name and address of any monitor. Page 6 of 16

4 MANUFACTURING INFORMATION A description of the methods, facilities, and controls used for the manufacture, processing, storage, and, where appropriate, installation of the device, in sufficient details so that a person generally familiar with good manufacturing practice can make a knowledgeable judgment about the quality control used in the manufacture of the device. Page 7 of 16

5 EXAMPLE OF THE INVESTIGATORS AGREEMENT An example of the agreement to be entered into by all investigators to comply with investigator obligations stated under part 812, and a list of the names and addresses of all investigators who have signed the agreement. Investigators CV should be attached as a part of this section. When applicable a statement of the investigator's relevant experience (including the dates, location, extent and type of experience); If the investigator was involved in an investigation or other research that was terminated, an explanation of the circumstances that led to termination; and a statement of the investigator's commitment to: 1. conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA; 2. supervise all testing of the device involving human subjects; and 3. ensure that the requirements for obtaining informed consent are met 4. Investigator s commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Page 8 of 16

6 INVESTIGATOR CERTIFICATION A certification that all investigators who will participate in the investigation have signed the agreement, that the list of investigators includes all the investigators participating in the investigation, and that no investigator will be added to the investigation until they have signed the agreement. Page 9 of 16

7 IRB S INFORMATION A list of the name, address, and chairperson of each IRB that has been or will be asked to review the investigation and a certification of the action concerning the investigation taken by such IRB. Page 10 of 16

8 NAME AND ADDRESS OF THE INVESTIGATIONAL INSTITUTIONS The name and address of any institution at which a part of the investigation may be conducted. Page 11 of 16

9 FINANCIAL CLAIMS State if device will be sold. If yes, please state the amount to be charged and an explanation of why sale does not constitute commercialization of the device. Page 12 of 16

10 ENVIRONMENTAL ASSESSMENT Per Device Advice on the CDRH Web site, http://www.fda.gov/cdrh/devadvice/ide/application.shtml, an environmental assessment as required under 21 CFR 25.40 or a claim for categorical exclusion under 21 CFR 25.30 or 25.34 is no longer required. Page 13 of 16

11 LABELING Copies of all labeling for the device. The labeling should contain the statement "CAUTION-Investigational Device. Limited by Federal (or United States) Law to Investigational Use." [ 812.5(a))]. Page 14 of 16

12 INFORMED CONSENT Copies of all forms and informational materials to be provided to subjects to obtain informed consent. Page 15 of 16

13 ADDITIONAL INFORMATION Any other relevant information FDA requests for review of the application. This is a good place to include the list any references you are attaching to the application. Page 16 of 16